全球慢性完全閉塞（CTO）器材市場：市場規模、佔有率和趨勢分析（2025-2032 年）

全球慢性完全閉塞裝置市場報告

2025 年全球慢性完全閉塞 (CTO) 器材市場規模為 2.14 億美元。在預測期內，該市場預計將以 2.7% 的複合年成長率成長，到 2032 年將達到 2.57 億美元。

• 這份關於慢性完全閉塞（CTO）器材的全球市場綜合報告涵蓋七個地區：北美、拉丁美洲、西歐、中東歐、中東、亞太地區和非洲。報告針對每個地區提供詳細的市場規模、銷售分析和平均售價數據，並預測至2032年的未來市場趨勢。與附件範例文件類似，本報告遵循成熟的結構，首先是執行摘要，然後逐步深入市場動態、市場細分、競爭格局以及報告的策略價值。

本報告聚焦於全球CTO器材市場，並對再入和再通器材技術進行了詳細分析。報告基於截至2022年的歷史數據，定量呈現了銷售量、手術例數、平均售價、市場規模、市場佔有率、成長趨勢以及至2032年的預測。此外，報告還分析了近期併購、公司概況、產品系列以及主要競爭對手。

整體而言，全球慢性完全閉塞病變（CTO）器械市場最好被理解為一個專注於特定應用的基礎技術市場。雖然該市場並非血管內治療的唯一驅動力，但它在最具挑戰性的病例中發揮著至關重要的作用，能夠支持後續治療階段的發展。正因如此，即使醫保報銷方面的挑戰、醫生的保守態度以及價格敏感性阻礙了市場擴張，該類別仍然佔據著重要的地位。

市場概覽

全球慢性完全閉塞（CTO）器械市場涵蓋了專門設計的器械，旨在幫助醫生在血管內治療中克服慢性完全閉塞（CTO）。當標準導管導引線或親水性導管無法單獨通過病變時，即可使用這些器械。在這種情況下，專門的CTO技術有助於穿過或繞過閉塞部位，從而建立通路並輸送其他治療器械。

該市場的主要特徵在於手術必要性與醫生實踐之間的矛盾。某些慢性閉塞病變僅靠導管導引線難以處理，此時，CTO器械便成為實用且往往不可或缺的解決方案。然而，由於對傳統導絲的熟悉程度以及標準導絲與專用CTO系統之間顯著的價格差異，許多專家仍然傾向於首先嘗試使用傳統導管導引線通過病變部位。因此，CTO器械的使用往往是選擇性的，而非常規的。

由於這些器械能夠輔助手術操作，其市場成長與周邊血管介入治療日益複雜密切相關。隨著越來越多的患者病情發展至晚期、合併症增多、鈣化病變增多，對專業化血管介入技術的需求預計將持續旺盛。然而，這種重要性並不一定能轉化為市場的快速成長，因為成本和報銷機制仍然會影響技術的普及趨勢。

市場促進因素

CTO元件的新應用

全球慢性完全閉塞病變（CTO）介入器材市場的主要促進因素之一是這些器材適應症的不斷擴大。貝克頓·迪金森公司（Becton Dickinson）的Crosser導管最初是為CTO介入治療而開發和銷售的，但後來也獲準用於動脈粥狀硬化斑塊切除術（切除術斑塊）。 Invamed公司及其Temren動脈粥狀硬化斑塊切除術器械（也可用作CTO介入導管）也呈現類似的模式。這點意義重大，因為與單純的CTO介入治療相比，動脈粥狀硬化斑塊切除術術通常能獲得更高的保險報銷比例。

當一款設備既能滿足日常工作流程的需求，又能用於醫保覆蓋的斑塊清除手術時，其價值提案便會提升。這使得製造商能夠設定更高的價格，從而為醫生提供更有力的理由採用該產品。如果更多競爭對手效倣此策略，CTO設備市場可望受益於更廣泛的功能定位和更充分的經濟效益證明。

血管內治療的發展

血管內治療的整體成長也推動了對慢性完全阻塞（CTO）介入器械的需求。在部署球囊或支架之前，導管導引線必須先到達狹窄或閉塞區域。雖然在許多手術中這很容易做到，但在更具挑戰性的慢性完全阻塞（CTO）病例中，標準導管導引線可能無法到達目標位置。 CTO介入器材正是為了解決這些情況而設計的。

簡而言之，該市場與血管內手術總數密切相關，但尤其受到複雜病例增加的顯著影響。隨著周邊血管介入治療的擴展，對專用血管通路支架的需求也日益成長，尤其是在晚期疾病或嚴重鈣化患者。因此，該市場不僅與手術數量的增加密切相關，也與技術難度較高的手術數量的增加密切相關。

BTK生長及其應對力

CTO介入器材市場對膝下（BTK）手術數量的增加以及合併多種疾病的患者群體日益成長尤為敏感。這些患者的病灶更可能有高鈣化、長段病灶或其他難以通過的情況。在這種情況下，標準導管導引線的限制就更加明顯，專用CTO介入器材的價值也隨之提升。

隨著糖尿病患者人數持續成長，以及老年族群中晚期周邊血管疾病的日益普遍，預計對這些輔助技術的需求將保持穩定。即使只有一小部分手術需要特殊的血管通路輔助，手術數量的增加仍可能導致相關病例絕對數量的顯著成長。

市場限制

缺乏還款機制

全球慢性完全閉塞病變（CTO）器械市場面臨的最大阻礙因素是缺乏保險報銷。 CTO器材價格昂貴，在許多歐洲國家，其使用不被視為可單獨報銷的醫療程序。當醫院和醫生被迫承擔這筆費用而無法獲得額外補償時，他們往往會避免使用該產品，除非絕對必要。

這會對其使用產生顯著影響。由於許多病灶仍有其他治療途徑，醫師通常會先嘗試成本較低的方案。實際上，這意味著CTO器械通常僅用於最棘手的病例。因此，缺乏健保報銷限制了市場規模和用藥習慣的養成，因為醫生不太可能對那些經濟上難以證明其合理性的產品建立常規使用習慣。

患者選擇和適應症的不確定性

另一個重要的阻礙因素是缺乏關於患者選擇和再入裝置合理使用的明確指南。由於醫生之間對於何時使用產品缺乏廣泛指南，其應用會變得更加謹慎和選擇性。這在技術複雜、學習曲線較長的手術中尤其明顯。

這種不確定性會帶來兩方面的影響。首先，它限制了醫生能夠自信地使用該設備的病例數。其次，它可能會讓一些醫生猶豫是否要投入時間來掌握高水準的操作技能。在一個產品成功與否很大程度上取決於醫生信心和經驗的市場中，這可能成為產品推廣應用的一大障礙。

與導管導引線相比，成本更高

與導管導引線相比，較高的成本仍然是一個直接且持續的限制因素。標準親水性導管的導管導引線遠低於專用再入和再通系統。由於許多病變僅需導管導引線即可通過，因此醫生必須確信 CTO 器械具有足夠的臨床價值，足以抵消其成本。

對一些專家來說，這種論點仍然不夠令人信服。有些醫師仍不確定專用CTO器材是否能節省足夠的時間或有效發揮作用，證明其高昂的平均售價（ASP）是合理的。基於導管導引線的穿刺技術仍然很常見且易於理解，這使得突破既有的診療模式變得困難。這就造成了一種市場局面：產品的價值必須在具體病例中重複驗證。

市場覆蓋範圍和數據範圍

定量研究範圍

市場規模、市佔率、市場預測、市場成長率、銷售量、平均售價。

定性研究範圍

市場促進因素和阻礙因素、市場規模和成長趨勢、近期併購、公司簡介、產品系列和主要競爭對手。

目標期

基準年：2025 年，歷史資料：截至 2022 年，預測：截至 2032 年。

按地區定位

北美洲、拉丁美洲、西歐、中歐和東歐、中東、亞太地區、非洲。

包含的資料類型

銷售量、平均售價、治療次數、市場規模和成長趨勢。

本報告結合了詳細的定量分析和可操作的市場背景，使用戶能夠評估 CTO 設備在更廣泛的血管內治療中的地位，以及該類別未來將如何發展。

目標市場及區隔

• 本報告涵蓋用於治療慢性完全閉塞（CTO）的器械全球市場，並進一步細分為以下幾類：

再入裝置

這些裝置旨在幫助醫生在繞過難以處理的阻塞部位後重新進入真腔。它們在解剖結構複雜、存在內膜下移位或病變路徑需要可控重新進入的情況下特別有用。

重連裝置

這些裝置用於在閉塞部位內創建或維持通道，幫助導管導引線和其他器械通過嚴重的狹窄或鈣化病變。

競爭分析

近年來，美敦力在慢性完全閉塞病變（CTO）器械領域的地位發生了顯著變化。 2013年8月之前，美敦力銷售「Pioneer Plus」系列再入導管，但該產品線隨後被Volcano收購。 2015年1月，美敦力收購Covidien後，在該領域的格局進一步改變。目前，美敦力正在推廣“Entia再入系統”和“Viance穿刺導管”，在再入和經病變介入治療中均發揮積極作用。這使得美敦力成為一家實力雄厚的競爭對手，並擁有將CTO器械整合到更廣泛的血管內治療產品組合中的規模優勢。

2015年3月，康德樂（Cardinal Health）收購強生公司旗下的Cordis業務後，迅速成為慢性完全閉塞病變（CTO）介入器材市場的領導參與企業。該公司目前銷售其「Outback」再入器材和「Frontrunner」再通訊平台。康德樂充分利用其將這些CTO產品與其他血管內治療產品捆綁銷售的優勢，加強客戶關係並保持競爭優勢。該公司已在歐洲市場佔據主導地位，市佔率約佔一半，是該領域最重要的參與企業之一。

貝克頓·迪金森公司 (Becton Dickinson) 透過 2012 年收購 FlowCardia 公司，鞏固了其在慢性動脈粥狀硬化斑塊切除術(CTO) 器械市場的地位。此次收購將 Crosser 器械納入了 BD 的產品系列。 Crosser 器械已於 2007 年獲得 FDA核准，並於 2011 年獲得動脈粥樣斑塊切除術切除術。這項新增適應症具有重要的策略意義，因為醫生使用 CTO 器械無法獲得某些報銷，而將產品與動脈粥狀硬化斑塊切除術相結合，使其價值主張更具提案。這使得貝克頓·迪金森公司能夠在經濟效益往往難以論證的市場中成功地從競爭對手中脫穎而出。

總體而言，競爭格局是由產品系列的商品搭售、設備差異化以及在對成本敏感的外科手術環境中證明專業交叉產品合理性的能力所塑造的。

科技與醫療治療的發展趨勢

CTO器材市場的主要趨勢之一是穿通技術的持續創新。從影像引導工具到更專業的穿通系統，再連接和再入器械正在拓展醫生處理複雜病變時的可選擇方案。

另一個重要趨勢是透過增加適應症和擴展應用範圍來實現產品差異化。能夠同時支持慢性完全閉塞病變介入治療和動脈粥狀硬化斑塊切除術相關工作流程的器械正在市場上佔據更有利的經濟地位。

臨床診療模式仍然很大程度上取決於醫師的偏好。雖然有些醫生仍然習慣僅使用導管導引線進行介入治療，但越來越多的醫生開始採用專門的慢性完全閉塞病變介入工具來處理最具挑戰性的病變。這意味著產品的成功不僅取決於技術性能，還取決於培訓、習慣養成以及與工作流程的兼容性。

最後，血管內治療日益複雜化也帶動了市場發展。隨著膝下手術和鈣化病變治療被納入治療方案，儘管目前高階血管通路支援技術的應用仍有限，但其需求依然十分迫切。

地區

本報告提供了涵蓋北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的全球研究成果。

詳細的市場分析、市場區隔和預測數據，共 87 頁。

附錄：調查方法和縮寫詞彙表。

這份報告的意義

到 2032 年，全球 CTO 裝置市場最具吸引力的機會在哪裡？

在不同地區和治療環境中，再入和再穿透裝置的使用情況如何？

BTK手術、鈣化病變和複雜合併症將在未來市場成長中發揮什麼作用？

高平均售價 (ASP)、保險報銷不足以及醫生對導絲的偏好如何限制了導管導引線的更廣泛應用？

哪些公司在 CTO 設備市場處於領先地位？收購和產品商品搭售對它們的競爭對手有何影響？

在臨床作用明確但經濟效益仍面臨挑戰的市場中，供應商如何更有效地定位 CTO 設備？

iData Research 的《全球慢性完全閉塞 (CTO) 器械市場報告》透過詳細的市場區隔、競爭分析、定價數據和預測模型解答了這些問題。利用這份報告，您可以了解市場需求、比較競爭對手，並在血管內器械這一專業且至關重要的領域制定策略。

目錄

圖表清單

調查方法

• 第一步：計劃啟動與團隊組建
• 步驟 2：準備資料系統並進行二次調查。
• 步驟 3：設計和準備訪談和調查問卷。
• 第四步：進行初步調查
• 第五步：調查與分析：建立基準估計值
• 第六步：市場預測與分析
• 步驟 7：辨識策略機遇
• 步驟 8：最終審核和市場推廣
• 步驟九：客戶回饋與市場監測

全球關稅的影響

慢性完全閉塞治療器材市場

• 執行摘要
  • 全球慢性完全閉塞裝置市場概覽
  • 競爭分析
  • 目標程式
  • 目標市場
  • 目標區域
• 介紹
• 手術次數
  • 首席技術長 (CTO) 全部流程
  • 再入技術
  • 重新開放程序
• 市場概覽
  • 按細分市場
  • 按地區
• 市場分析與預測
  • 慢性完全閉塞治療器材市場
  • 再入設備市場
  • 重連設備市場
• 促進因素和抑制因素
• 競爭性市佔率分析

簡稱

Global Chronic Total Occlusion Device Market Report

The global chronic total occlusion device market was valued at $214 million in 2025. Over the forecast period, the market is expected to grow at a CAGR of 2.7% to reach $257 million by 2032.

• The full report suite on the global market for chronic total occlusion, or CTO, devices covers seven geographical regions: North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa. For each region, the report provides detailed market valuation, unit analysis and average selling price data, while also extending projections through 2032 to provide a forward-looking view of market performance. As with the attached example document, this description follows the same proven structure, moving from executive summary through market dynamics, segmentation, competition and strategic report value .

This report focuses on the global CTO device market and includes detailed analysis of re-entry and re-canalization device technologies. It quantifies unit sales, procedure numbers, average selling prices, market size, market shares, growth trends and forecasts through 2032, with historical data to 2022. In addition, the report includes recent mergers and acquisitions, company profiles, product portfolios and analysis of leading competitors.

Overall, the global CTO device market is best understood as a focused enabling technology market. It does not drive the endovascular procedure on its own, but it can make the rest of the procedure possible in the most difficult cases. That role keeps the category important, even as reimbursement challenges, physician conservatism and price sensitivity continue to limit broader expansion.

Market Overview

The global CTO device market includes devices specifically designed to help physicians cross chronic total occlusions during endovascular procedures. These devices are used when a lesion cannot be crossed with a standard guidewire or a hydrophilic guidewire alone. In these situations, dedicated CTO technologies can help create access through or around the occlusion so that other treatment devices can be delivered.

A defining characteristic of this market is the tension between procedural need and physician habit. Some chronic occlusions are clearly too challenging for guidewires alone, and in those cases CTO devices can offer a practical and often necessary solution. However, many specialists still prefer to attempt lesion crossing with conventional guidewires first, both because of familiarity and because of the large price difference between standard wires and dedicated CTO systems. As a result, CTO devices tend to be used selectively rather than routinely.

Because these devices are procedural enablers, market growth is closely linked to the complexity of peripheral vascular intervention. As more patients present with advanced disease, more comorbidities and more calcified lesions, the need for specialized crossing technologies should remain relevant. Still, that relevance does not automatically translate into rapid market growth because cost and reimbursement continue to shape adoption.

Market Drivers

New Indications for CTO Devices

One of the main drivers in the global CTO device market is the expansion of device indications. Becton Dickinson's Crosser catheter was originally developed and marketed for CTO crossing, but later gained an indication for atherectomy. A similar pattern occurred with Invamed and its Temren atherectomy device with CTO catheter functionality. This is important because atherectomy procedures generally have stronger reimbursement support than CTO crossing alone.

When a device can participate in both a crossing workflow and a reimbursable plaque modification procedure, its value proposition improves. This allows manufacturers to support higher pricing and gives physicians a stronger reason to adopt the product. If more competitors follow this strategy, the CTO device market could benefit from broader functional positioning and better economic justification.

Growth in Endovascular Treatments

CTO device demand is also supported by the growth of endovascular treatment overall. Before a balloon or stent can be deployed, a guidewire must first reach the stenosed or occluded segment. In many procedures this is straightforward, but in more difficult chronic total occlusions, standard guidewires may fail. CTO devices are designed for exactly these situations.

This means the market is tied to total endovascular procedure volume, but especially to growth in more complex cases. As peripheral intervention expands, particularly in patients with advanced disease or with heavy calcification, demand for specialized crossing support rises as well. The market is therefore not only linked to more procedures, but also to more technically difficult procedures.

Responsiveness to BTK Growth and Complex Comorbidities

The CTO device market is particularly responsive to growth in below-the-knee, or BTK, procedures and in patient populations with multiple comorbidities. These patients are more likely to have lesions that are highly calcified, long-segment or otherwise difficult to cross. In such cases, the limitations of standard guidewires become more obvious, increasing the value of a dedicated CTO device.

As diabetic populations continue to grow and as aging patient groups present with more advanced peripheral vascular disease, the need for these enabling technologies should remain stable. Even if only a fraction of total procedures require dedicated crossing support, the absolute number of relevant cases can still rise with procedure volume.

Market Limiters

Lack of Reimbursement

The biggest limiter in the global CTO device market is lack of reimbursement. The cost of a CTO device is high, and in many European countries the use of these devices is not considered a separately reimbursable procedure. When hospitals and physicians are forced to absorb this cost without additional payment, they are more likely to avoid the product unless it is absolutely necessary.

This has a major effect on utilization. Because other treatment pathways remain available for many lesions, physicians often try lower-cost options first. In practice, this means CTO devices are frequently reserved for only the most difficult cases. The lack of reimbursement therefore limits both market size and habit formation, since physicians are less likely to build routine usage patterns around a product that is hard to justify economically.

Patient Selection and Indication Uncertainty

Another key limiter is the lack of clear guidelines around patient selection and the appropriate use of re-entry devices. When physicians do not have strong consensus guidance on when a product should be used, adoption becomes more cautious and selective. This is especially true in technically demanding procedures where learning curves are already longer.

This uncertainty has two effects. First, it narrows the number of cases in which physicians feel comfortable using the device. Second, it discourages some operators from investing the time needed to become highly proficient. In a market where product success depends heavily on physician confidence and experience, this can be a meaningful adoption barrier.

High Cost Relative to Guidewires

High cost relative to guidewires remains a direct and persistent constraint. Standard and hydrophilic guidewires are much cheaper than dedicated re-entry and recanalization systems. Because many lesions can still be crossed with guidewires alone, physicians must be convinced that CTO devices offer enough procedural value to justify the expense.

For some specialists, that case has not yet been fully made. Some remain unconvinced that dedicated CTO devices save enough time or work effectively enough to offset their higher ASP. Since guidewire-based crossing remains common and well understood, switching away from that habit is difficult. This creates a market where product value must be proven repeatedly, case by case.

Market Coverage and Data Scope

Quantitative Coverage

Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.

Qualitative Coverage

Market drivers and limiters, market size and growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.

Time Frame

Base year 2025, historical data to 2022 and forecasts through 2032.

Regional Coverage

North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa.

Data Types Included

Unit sales, average selling prices, procedure numbers, market size and growth trends.

This report combines detailed quantitative analysis with practical market context, allowing users to evaluate where CTO devices fit within broader endovascular practice and how the category is expected to evolve over time.

Markets Covered and Segmentation

• The report covers the Global Chronic Total Occlusion Device Market, further segmented into:

Re-Entry Devices

These devices are designed to help physicians re-enter the true lumen after navigating around a difficult occlusion. They are especially relevant in complex anatomy where subintimal crossing has occurred or where the lesion path requires controlled re-entry.

Re-Canalization Devices

These devices are used to create or support a pathway through the occlusion itself, helping guidewires and other tools advance through heavily stenosed or calcified lesions.

Competitive Analysis

Over the last several years, Medtronic's position in the CTO device sector has changed significantly. Before August 2013, Medtronic marketed the Pioneer Plus re-entry catheter range, but that product line was later acquired by Volcano. After Medtronic acquired Covidien in January 2015, its presence in the category evolved further. Today, Medtronic promotes the Enteer Re-entry System and the Viance Crossing Catheter, giving it an active role in both re-entry and lesion-crossing workflows. This positions the company as a meaningful competitor with the scale to integrate CTO devices into a broader endovascular offering.

Cardinal Health became a major participant in the CTO device market after acquiring Johnson & Johnson's Cordis business in March 2015. The company currently markets the Outback re-entry device and the Frontrunner recanalization platform. Cardinal Health benefits from its ability to bundle these CTO products with other endovascular products, which can strengthen account relationships and support competitive positioning. The company also held a dominant position in Europe, with about half of the total market share, making it one of the most important players in the category.

Becton Dickinson strengthened its role in the CTO market through the acquisition of FlowCardia in 2012. That deal brought the Crosser device into BD's portfolio. The Crosser had already received FDA approval in 2007, and later gained an atherectomy indication in 2011. This added indication was strategically important because physicians do not receive reimbursement specifically for CTO device use, so linking the product to atherectomy created a more defensible value proposition. That helped Becton Dickinson stand out in a market where economic justification is often difficult.

Overall, the competitive landscape is shaped by portfolio bundling, device differentiation and the ability to justify specialized crossing products in a cost-sensitive procedural environment.

Technology and Practice Trends

One of the main trends in the CTO device market is continued innovation in crossing technology. Recanalization and re-entry devices now give physicians more options in how they approach difficult lesions, from image-guided tools to more specialized crossing systems.

Another important trend is the move toward product differentiation through added indications and broader procedural relevance. Devices that can support both CTO crossing and atherectomy-related workflows have a stronger economic position in the market.

Practice patterns also continue to reflect strong dependence on physician preference. Some physicians remain comfortable with guidewire-only approaches, while others increasingly adopt specialized CTO tools in the most difficult lesions. This means product success depends not only on technical performance, but also on training, habit and workflow fit.

Finally, the market benefits from rising endovascular complexity. As more BTK procedures and more calcified lesions enter treatment pathways, the need for advanced crossing support remains relevant even if use is still selective.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

87 pages of detailed market analysis, segmentation and forecast data.

Methodology Appendix and Acronym Glossary.

Why This Report

Where are the most attractive opportunities in the global CTO device market through 2032?

How are re-entry and re-canalization devices being adopted across different regions and procedural settings?

What role do BTK procedures, calcified lesions and complex comorbidities play in future market growth?

How do high ASPs, lack of reimbursement and physician preference for guidewires limit broader adoption?

Which companies lead the CTO device market, and how are acquisitions and product bundling shaping competition?

How can suppliers better position CTO devices in a market where the clinical role is clear, but the economic case remains challenging?

The Global Chronic Total Occlusion Device Market Report from iData Research answers these questions with detailed segmentation, competitive analysis, pricing data and forecast modeling. Use it to understand category demand, benchmark competitors and support strategy in a specialized but important endovascular device segment.

TABLE OF CONTENT

List Of Figures

List Of Charts

Research Methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems And Perform Secondary Research
• Step 3: Preparation For Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast And Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review And Market Release
• Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

Chronic Total Occlusion Device Market

• 9.1 Executive Summary
  • 9.1.1 Global Chronic Total Occlusion Device Market Overview
  • 9.1.2 Competitive Analysis
  • 9.1.3 Procedures Included
  • 9.1.4 Markets Included
  • 9.1.5 Regions Included
• 9.2 Introduction
• 9.3 Procedure Numbers
  • 9.3.1 Total Cto Procedures
  • 9.3.2 Re-Entry Procedures
  • 9.3.3 Recanalization Procedures
• 9.4 Market Overview
  • 9.4.1 By Segment
  • 9.4.2 By Region
• 9.5 Market Analysis And Forecast
  • 9.5.1 Total Chronic Total Occlusion Device Market
  • 9.5.2 Re-Entry Device Market
  • 9.5.3 Recanalization Device Market
• 9.6 Drivers And Limiters
  • 9.6.1 Market Drivers
  • 9.6.2 Market Limiters
• 9.7 Competitive Market Share Analysis

Abbreviations

LIST OF CHARTS

• Chart 9-1: CTO Device Market, Global, 2025 & 2032
• Chart 9-2: CTO Procedures, Global, 2025
• Chart 9-3: CTO Procedures by Region, Global, 2022 - 2032
• Chart 9-4: CTO Device Market by Segment, Global, 2022 - 2032
• Chart 9-5: CTO Device Market by Region, Global, 2022 - 2032
• Chart 9-6: Leading Competitors, CTO Device Market, Global, 2025

LIST OF FIGURES

• Figure 9-1: CTO Device Procedures Covered
• Figure 9-2: CTO Device Markets Covered
• Figure 9-3: CTO Device Regions Covered, Global (1 of 2)
• Figure 9-4: CTO Device Regions Covered, Global (2 of 2)
• Figure 9-5: CTO Procedures by Segment, Global, 2022 - 2032
• Figure 9-6: CTO Procedures by Region, Global, 2022 - 2032
• Figure 9-7: CTO Procedures by Country, North America, 2022 - 2032
• Figure 9-8: CTO Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 9-9: CTO Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 9-10: CTO Procedures by Country, Western Europe, 2022 - 2032
• Figure 9-11: CTO Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 9-12: CTO Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 9-13: CTO Procedures by Country, Middle East, 2022 - 2032
• Figure 9-14: CTO Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 9-15: CTO Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 9-16: CTO Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 9-17: CTO Procedures by Country, Africa, 2022 - 2032
• Figure 9-18: Re-Entry Procedures by Region, Global, 2022 - 2032
• Figure 9-19: Re-Entry Procedures by Country, North America, 2022 - 2032
• Figure 9-20: Re-Entry Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 9-21: Re-Entry Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 9-22: Re-Entry Procedures by Country, Western Europe, 2022 - 2032
• Figure 9-23: Re-Entry Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 9-24: Re-Entry Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 9-25: Re-Entry Procedures by Country, Middle East, 2022 - 2032
• Figure 9-26: Re-Entry Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 9-27: Re-Entry Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 9-28: Re-Entry Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 9-29: Re-Entry Procedures by Country, Africa, 2022 - 2032
• Figure 9-30: Recanalization Procedures by Region, Global, 2022 - 2032
• Figure 9-31: Recanalization Procedures by Country, North America, 2022 - 2032
• Figure 9-32: Recanalization Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 9-33: Recanalization Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 9-34: Recanalization Procedures by Country, Western Europe, 2022 - 2032
• Figure 9-35: Recanalization Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 9-36: Recanalization Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 9-37: Recanalization Procedures by Country, Middle East, 2022 - 2032
• Figure 9-38: Recanalization Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 9-39: Recanalization Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 9-40: Recanalization Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 9-41: Recanalization Procedures by Country, Africa, 2022 - 2032
• Figure 9-42: CTO Device Market by Segment, Global, 2022 - 2032 (US$M)
• Figure 9-43: CTO Device Market by Region, Global, 2022 - 2032 (US$M)
• Figure 9-44: Total CTO Device Market, Global, 2022 - 2032
• Figure 9-45: Units Sold by Region, CTO Device Market, Global, 2022 - 2032
• Figure 9-46: Average Selling Price by Region, CTO Device Market, Global, 2022 - 2032 (US$)
• Figure 9-47: Market Value by Region, CTO Device Market, Global, 2022 - 2032 (US$M)
• Figure 9-48: Re-Entry Device Market, Global, 2022 - 2032
• Figure 9-49: Units Sold by Region, Re-Entry Device Market, Global, 2022 - 2032
• Figure 9-50: Average Selling Price by Region, Re-Entry Device Market, Global, 2022 - 2032 (US$)
• Figure 9-51: Market Value by Region, Re-Entry Device Market, Global, 2022 - 2032 (US$M)
• Figure 9-52: Recanalization Device Market, Global, 2022 - 2032
• Figure 9-53: Units Sold by Region, Recanalization Device Market, Global, 2022 - 2032
• Figure 9-54: Average Selling Price by Region, Recanalization Device Market, Global, 2022 - 2032 (US$)
• Figure 9-55: Market Value by Region, Recanalization Device Market, Global, 2022 - 2032 (US$M)
• Figure 9-56: Leading Competitors, CTO Device Market, Global, 2025